Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	1900.0430002/JMC/MBT	
First Inventor	SALZWEDEL et al.	
Title	Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer.	
Express Mail Label No.	Peptide I Protein	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450		
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. 3. Specification [Total Pages 7.3] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s)		7. CD2ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on:		
		<u></u>	D-R (2 copies); or	
		c. Statements verifying identity of above copies		
		ACCOMPANYING APPLICATION PARTS		
4. X Drawing(s) 5. Oath or Declara. a. Newly b. Copy in (for column) i. DE Signar 1.6 6. X Applica 18. If a CONTINU specification following application infor For CONTINUATION 5b. is considered a	rexecuted (original or copy) from a prior application (37 CFR 1.63(d)) intinuation/divisional with Box 18 completed) ELETION OF INVENTOR(S) med statement attached deleting inventor(s) me in the prior application, see 37 CFR 3(d)(2) and 1.33(b). Ition Data Sheet. See 37 CFR 1.76 ING APPLICATION, check appropriate box, and supporting the title, or in an Application Data Sheet under 3: tion Divisional Continual continuation: continual continual	10. 37 CFR 3.73(b) Statemed (when there is an assign English Translation Doc 12. Information Disclosure Statement (IDS)/PTO-14. 13. Preliminary Amendment Return Receipt Postcard (Should be specifically in Certified Copy of Priority (if foreign priority is clair Nonpublication Request (b)(2)(B)(i). Applicant multiple of the requisite information below and Tock 1.76: tion-in-part (CIP) of prior application and is hereby or divisional application and is hereby	Attorney nument (if applicable) Copies of IDS 449 Citations Id (MPEP 503) temized) y Document(s) ned) it under 35 U.S.C. 122 sust attach form PTO/SB/35 ander 37CFR 1.136(a)(3) e assignee is: and in the first sentence of the on No.:	
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS				
X Customer	Number: 26111	OR Corre	spondence address below	
Name Sterne, Kessler, Goldstein & Fox P.L.L.C.				
Address				
City		State	Zip Code	
Country		elephone	Fax	
Name (Print/Type)	indi j Di Tung	Registration No. (Attorney/Agent)	50,007 Date Age 20,24	
Signature	Mars B Dim		Date Jan 29, 2004	

This collection of information is required by 37 CFR 1.53(p) The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Robert W. Esmond Tracy-Gene G. Durkin Michael A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Lawrence B. Bugaisky Donald J. Featherston Michael V. Messinger

Judith U. Kim Juditi U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono

Theodore A. Wood Elizabeth J. Haanes Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottlingham Christine M. Hullier Rae Lynn Prengaman Jane Shershenovich* Lawrence J. Carroll* George S. Bardmesser Daniel A. Kleir Rodney G. Maze Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* Jon E. Wright* LuAnne M. Yuricek*

John J. Figueroa Ann E. Summerfield Registered Patent Agents • Karen R. Markowicz Nancy J. Leith Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Mary B. Tung Katrina Y. Pei Bryan L. Skelton

Robert A. Schwartzman Timothy A. Doyle Jennifer R. Mahalingappa

Mail Stop Patent Application

Teresa A. Colella

Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes

Of Counsel Kenneth C. Bass III Evan R. Smith

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

January 29, 2004

WRITER'S DIRECT NUMBER: (202) 772-8840 **INTERNET ADDRESS:** MTUNG@SKGF.COM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be assigned; Filed: January 29, 2004

Inhibition of HIV-1 Replication by Disruption of the Processing of the

Viral Capsid-Spacer Peptide 1 Protein

Inventors:

SALZWEDEL et al.

Our Ref:

1900.0430002/JMC/MBT

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. USPTO Utility Patent Application Transmittal Form PTO/SB/05;
- 2. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time;
- U.S. Utility Patent Application entitled:

Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein

and naming as inventors:

Karl SALZWEDEL Feng LI Carl T. WILD Graham P. ALLAWAY Eric O. FREED

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents January 29, 2004 Page 2

the application comprising:

- a. an Application Data Sheet (37 C.F.R. § 1.76);
- b. specification containing:
 - i. 60 pages of description prior to the claims;
 - ii. 12 pages of claims (81 claims);
 - iii. a one (1) page abstract;
- c. 11 sheets of drawings: (Figures 1-10); and
- 4. Two (2) return postcards.

Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

Mary B. Tung

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mary B. Tung

Agent for Applicants Registration No. 50,007

JMC/MBT/lam
Enclosures

224030.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SALZWEDEL et al.

Appl. No.: To be assigned

Filed: January 29, 2004

For: Inhibition of HIV-1 Replication by Disruption of the Processing of the

Viral Capsid-Spacer Peptide 1

Protein

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 1900.0430002/JMC/MBT

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mary B. Tung

Agent for Applicants

Registration No. 50,007

Date: January 29, 2004 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600